WHO approves Bavarian Nordic’s mpox vaccine

The World Health Organization has approved a new mpox vaccine developed by Bavarian Nordic, marking a significant step in addressing the ongoing outbreaks in Africa, which have resulted in at least 643 fatalities this year. The vaccine is intended for individuals aged 18 and older, administered in two doses, but the WHO has indicated that it may also be used off-label for infants, children, pregnant women, and immunocompromised individuals when the benefits outweigh risks. Additionally, the organization recommends a single-dose option in situations where vaccine supplies are limited, emphasizing the importance of monitoring safety and efficacy. Bavarian Nordic announced its capability to produce an additional 50 million doses of the vaccine within the next 12 to 18 months, contingent upon regulatory approvals and demand. This production increase comes on top of the previously stated 13 million doses expected to be available by the end of next year. The company is actively engaging with global medicine regulators to expedite the manufacturing process, which could involve local partners in the regions affected by the outbreak. Despite the approval, the WHO has faced criticism regarding the delay in authorizing mpox vaccines, especially given the prolonged nature of outbreaks in Africa. Prior to this approval, the WHO had already permitted organizations like GAVI and UNICEF to procure vaccines, pending official authorization. This move reflects a growing urgency to combat the mpox virus and protect vulnerable populations. The approval of the vaccine is a crucial development in public health efforts to mitigate the impact of mpox, particularly in regions severely affected by the disease. As the situation evolves, the WHO and Bavarian Nordic's collaboration may lead to improved access to vaccines and a more effective response to future outbreaks.